Form 4: Globus Medical Director Sells Shares Under 10b5-1 Plan

A director at Globus Medical Inc. sold 2,000 shares of Class A Common Stock for $101.1 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Leslie V Norwalk, a director of Globus Medical Inc. (GMED), sold 2,000 shares of Class A Common Stock.
• The transaction occurred on January 8, 2026, at a price of $101.1 per share.
• Following this sale, Leslie V Norwalk beneficially owns 10,419 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan established on September 12, 2025.

Sentiment

Score: 5

Explanation: The sale by a director, while a reduction in ownership, was executed under a pre-established 10b5-1 trading plan, which typically mitigates the negative sentiment associated with insider selling, rendering the event largely neutral.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• A director reduced their direct ownership in the company by 2,000 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A director's sale, even if planned, might be viewed with slight caution, but the 10b5-1 plan reduces concerns about adverse non-public information.

Key Dates

Recommendation

The filing reports a pre-planned sale by a director under a 10b5-1 plan. This type of transaction is generally considered neutral as it is not indicative of new, material non-public information. It does not provide sufficient new information to warrant a change in investment recommendation based solely on this filing.

Keywords

Globus Medical, GMED, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction, Class A Common Stock